Biotech startup AviadoBio emerges with $80M for neuro disorder gene therapies

 

A biotech company with an answer for one of the challenges facing gene therapies for neurodegenerative disorders is out of stealth with a former Novartis executive at the helm and $80 million to support its research.

The lead program of AviadoBio is a gene therapy for frontotemporal…